Ingo Schubert

Title: Ingo Schubert: Innovator in Myeloid Binding Technology

Introduction

Ingo Schubert is a notable inventor based in Baiersdorf, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of myeloid binding technologies. His work focuses on creating innovative solutions for medical applications, especially in the treatment of acute myeloid leukaemia and myelodysplastic syndrome.

Latest Patents

Ingo Schubert holds a patent for a "CD33-, CD16- and CD123-specific single chain triplebody." This invention relates to a nucleic acid molecule that encodes a chain myeloid capable of specifically binding to CD33, CD16, and CD123. The patent outlines various components of the nucleic acid molecule, including specific sequences and modifications that enhance its binding capabilities. The invention also includes vectors, host cells, and methods for producing the single chain myeloid, which are crucial for potential therapeutic applications.

Career Highlights

Ingo Schubert is affiliated with Friedrich-Alexander-Universität Erlangen-Nürnberg, where he engages in research and development in the field of biotechnology. His work has led to advancements in understanding and treating hematological conditions, showcasing his commitment to improving patient outcomes through innovative research.

Collaborations

Ingo Schubert has collaborated with notable colleagues such as Todd Braciak and Claudia C. Roskopf. These partnerships have fostered a collaborative environment that enhances the research and development process, leading to impactful innovations in the field.

Conclusion

Ingo Schubert's contributions to biotechnology, particularly through his patent on myeloid binding technology, highlight his role as an innovator in the medical field. His work continues to pave the way for advancements in treatments for serious health conditions.